Lead Principal Scientist

Camille Brochier

Immunology, Cardiovascular, Metabolism, Rare Hematological Diseases

“At Institut Roche, we work at the crossroad of industry and academia. We are lucky to work everyday with the best international scientists, and foster meaningful research collaborations that will directly benefit human health.”

Your role at Institut Roche and brief presentation of your professional background:

I joined the Roche Institute in 2018 as a scientific project manager. Since 2024 as Senior Scientific Project Manager, my mission is to work with Roche R&D teams to find the expertise and external resources needed to accelerate scientific discoveries to bring new treatments to patients.
In other words, I am involved in the identification, implementation and long-term management of collaborative translational research programmes between our R&D teams and the academic/university world. I’m also lucky enough to be a PhD supervisor, helping to train the next generation of researchers.

A molecular neurobiologist by training (Ph.D. from Paris-Saclay University, France), I also hold a Master in Biopharmaceutical Management (ESCP Europe business school). I have worked over 10 years in academia, first as a postdoctoral researcher at the Burke Neurological Institute (White Plains, NY) and then as Junior Faculty at Weill Cornell Medicine (New York, NY).

My Focus at Institut Roche:

At Institut Roche, my work focuses on Immunology, Cardiovascular, Metabolism, Rare Hematological Diseases

  1. Atsou S, et al. (2024) “Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab”. J Thromb Haemost. 22(1):112-125.
  2. Hammoudi N, et al.(2022).” Autologous organoid co-culture model reveals T cell-driven epithelial cell death in Crohn’s Disease”. Front Immunol. 13:1008456.
  3. Sefiane T, et al.(2025) “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice.” Haematologica.
  4. Mutala, L. B., et al. (2021). “The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.” Cancers (Basel) 13(2).
  5. Brochier, C*., et al. (2015). “Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration.” Proc Natl Acad Sci U S A 112(49): 15220-15225.
  6. Segretti, M. C., et al. (2015). “Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function.” ACS Med Chem Lett 6(11): 1156-1161.
  7. Aleyasin, H., et al. (2015). “Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.” Antioxid Redox Signal 22(2): 121-134.
  8. Brochier, C., et al. (2013). “Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.” J Neurosci 33(20): 8621-8632.
  9. Brochier, C*. and B. Langley (2013). “Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases.” Neurotherapeutics 10(4): 817-830.
  10. Butler, K. V., et al. (2010). “Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.” J Am Chem Soc 132(31): 10842-10846.
  11. Langley B, Brochier C, Rivieccio MA. (2009).”Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke”. Stroke 40(8):2899-905.
  12. Rivieccio, M. A., Brochier C et al. (2009). “HDAC6 is a target for protection and regeneration following injury in the nervous system.” Proc Natl Acad Sci U S A 106(46): 19599-19604.
  13. Brochier, C., et al. (2008). “Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models.” Physiol Genomics 33(2): 170-179.
  14. de Chaldée M, Brochier C et al. (2006). “ Capucin: a novel striatal marker down-regulated in rodent models of Huntington disease”. Genomics 87(2):200
    *corresponding author
More publications